Methods for the treatment of dyskinesia in cerebral palsy

Abstract

The disclosure is directed to methods of treating dyskinesia in cerebral palsy in human patients using deutetrabenazine and its active metabolites.

1 - 18 . (canceled) 
     
     
         19 . A method of treating dyskinesia in cerebral palsy in a human patient who is 6 through 18 years of age with DCP with predominant choreiform movement disorder, comprising administering to the patient a therapeutically effective amount of a compound having Formula (I): 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salt thereof, wherein each position represented as D has deuterium enrichment of no less than about 10%. 
     
     
         20 . The method of  claim 19 , wherein the patient has had cerebral palsy (CP) symptoms since infancy (≤2 years of age). 
     
     
         21 . The method of  claim 20 , wherein the patient has had nonprogressive CP symptoms since infancy. 
     
     
         22 . The method of  claim 19 , wherein the administering to the patient comprises administering a therapeutically effective amount to the patient of a daily amount of about 6 mg/day to about 48 mg/day, in one or two doses. 
     
     
         23 . The method of  claim 19 , wherein the treating results in maintaining or reducing abnormal involuntary movements associated with dyskinesia in cerebral palsy in the patient, relative to the patient's abnormal involuntary movements at baseline. 
     
     
         24 . The method of  claim 23 , wherein the abnormal involuntary movements associated with dyskinesia in cerebral palsy are of dystonic type. 
     
     
         25 . The method of  claim 23 , wherein the abnormal involuntary movements associated with dyskinesia in cerebral palsy are of choreiform type. 
     
     
         26 . The method of  claim 23 , wherein the abnormal involuntary movements associated with dyskinesia in cerebral palsy are measured by at least one of the rating scales:
 a) the MD-CRS part II;   b) the MD-CRS part I;   c) the CaGI-I; and   d) the CGI-I.   
     
     
         27 . The method of  claim 26 , wherein the abnormal involuntary movements associated with dyskinesia in cerebral palsy are reduced by at least 20% relative to the patient's abnormal involuntary movements at baseline. 
     
     
         28 . The method of  claim 26 , wherein the patient exhibits a reduction in the MD-CRS part II total score of at least 0.5 points, relative to baseline. 
     
     
         29 . The method of  claim 26 , wherein the patient exhibits a reduction in the MD-CRS part I total score of at least 2 points, relative to baseline. 
     
     
         30 . The method of  claim 23 , wherein the patient weighs at least 12 kg at baseline. 
     
     
         31 . The method of  claim 30 , wherein the patient weighs 12 kg to <17 kg at baseline and wherein the daily amount of deutetrabenazine administered is less than or equal to about 24 mg if the patient does not have a CYP2D6 impairment; or less than or equal to about 12 mg if the patient has a CYP2D6 impairment. 
     
     
         32 . The method of  claim 30 , wherein the patient weighs 17 kg to <30 kg at baseline and wherein the daily amount of deutetrabenazine administered is less than or equal to about 30 mg if the patient does not have a CYP2D6 impairment; or less than or equal to about 18 mg if the patient has a CYP2D6 impairment. 
     
     
         33 . The method of  claim 30 , wherein the patient weighs 30 kg to <40 kg at baseline and wherein the daily amount of deutetrabenazine administered is less than or equal to about 42 mg if the patient does not have a CYP2D6 impairment; or less than or equal to about 24 mg if the patient has a CYP2D6 impairment. 
     
     
         34 . The method of  claim 30 , wherein the patient weighs ≥40 kg at baseline and wherein the daily amount of deutetrabenazine administered is less than or equal to about 48 mg if the patient does not have a CYP2D6 impairment; or less than or equal to about 36 mg if the patient has a CYP2D6 impairment. 
     
     
         35 . The method of  claim 19 , wherein each position represented as D has deuterium enrichment of no less than about 50%. 
     
     
         36 . The method of  claim 19 , wherein each position represented as D has deuterium enrichment of no less than about 90%. 
     
     
         37 . The method of  claim 19 , wherein each position represented as D has deuterium enrichment of no less than about 98%. 
     
     
         38 . The method of  claim 19 , wherein each position represented as D has deuterium enrichment of no less than about 99%.